

1 Title

2 WHAT ABOUT USING SNIFFIN' STICKS 12 SCREENING TEST TO IDENTIFY POST-COVID-19
3 OLFACTORY DISORDERS?

4

5 Authors

6 Clair Vandersteen¹, Magali Payne^{2,3}, Louise-Émilie Dumas⁴, Alexandra Plonka^{2,5}, Grégoire
7 D'Andrea¹, David Chirio⁶, Élisabeth Demonchy⁶, Karine Risso⁶, Florence Askenazy-Gittard⁴, Nicolas
8 Guevara¹, Laurent Castillo¹, Valeria Manera^{2,3}, Auriane Gros^{2,3}

9

10 Affiliation

11 ¹Institut Universitaire de la Face et du Cou, 31 Avenue de Valombrose, 06100, Centre Hospitalier Universitaire, Université
12 Côte d'Azur, Nice, Alpes-Maritimes, France

13 ²Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, laboratoire CoBTek, Service Clinique Gériatrique du
14 Cerveau et du Mouvement, Nice, France

15 ³Université Côte d'Azur, Département d'Orthophonie de Nice, UFR Médecine, Nice, France.

16 ⁴Hôpitaux Pédiatriques de Nice CHU-LENVAL, 57 Avenue de la Californie, 06200, Centre Hospitalier Universitaire, Université
17 Côte d'Azur, Nice, Alpes-Maritimes, France

18 ⁵Institut NeuroMod, INRIA Centre de recherche Sophia Antipolis, 2004 Route des Lucioles, 06902, Université Côte d'Azur,
19 Sophia Antipolis, Alpes-Maritimes, France

20 ⁶Département de médecine infectiologique, hôpital de l'archet, 151 route de Saint-Antoine, 06200, Centre Hospitalier
21 Universitaire, Université Côte d'Azur, Nice, Alpes-Maritimes, France

22

23 **ABSTRACT**

24

25 **Background:** *Olfactory impairment is a major sequela of SARS-CoV-2 infection and has a*
26 *negative impact on daily life quality. Olfactory loss can be assessed in many ways but seems*
27 *to be little realized in a daily clinical practice. The sniffin Sticks test – 12 items (SST-12) can be*
28 *used in quick olfactory disorders screening. Its use in a post-covid19 situation was the main*
29 *objective of this work.*

30 **Methodology:** *Consecutive patients consulting to the ENT department with post-Covid-19*
31 *olfactory loss were included. The clinical examination included an analog scale for the self-*
32 *assessment of olfactory recovery (VAS), self-reported salt and sugar intake, a nasofibroscope,*
33 *the complete Sniffin' Stick Test (SST) and the SST-12.*

34 **Results:** *Among the 54 patients included, based on the SST-12, 14,8% (n=8) of the patients*
35 *could be classified as normosmic ($SST-12 \geq 11$), 48,1% (n=26) as hyposmic ($6 < SST-12 < 10$) and*
36 *37% (n=20) as functional anosmic ($SST-12 \leq 6$). We report excellent and significant correlations*
37 *between SST-12 and SST or VAS assessments. Salt and Sugar increased intake seems*
38 *significantly related to SST-12 results.*

39 **Conclusions:** *SST-12 is a reliable way to screen post-COVID-19 olfactory disorders could be*
40 *used in a daily clinical practice and might be used to prevent bad diet habits and so*
41 *cardiovascular risk.*

42

43

44

45

46

47 INTRODUCTION

48

49 The onset of a sudden partial (hyposmia) or total (anosmia) loss of smell is now
50 recognized as highly predictive of SARS-COV-2 infection⁽¹⁾. Anosmia can be the only COVID-19
51 symptom in 11 to 26% of cases⁽²⁻⁴⁾. The long-term anosmia can cause an alteration in the
52 quality of life⁽⁵⁾ and psychiatric disorders such as depression^(6,7), anxiety, anorexia⁽⁸⁾ and its
53 nutritional consequences⁽⁹⁾, social interaction disorders^(10,11) and cognitive impairment^(10,12,13).
54 So, the diagnosis of olfactory disorders and their management is essential especially as 6⁽¹⁴⁾
55 and 12⁽¹⁶⁾ months after the COVID-19 infection, respectively 60% and 30% of patients retain
56 an olfactory complaint and require attention. Moreover, even if sweet, salty, sour and bitter
57 tastes improved from 60% (acute COVID-19) to 97.2% (6 months) of patients⁽¹⁴⁾, salt and sugar
58 intake increase concerned near 30% of post-COVID-19 patients⁽¹⁵⁾, especially young women.
59 These findings should require patient's education to prevent cardiovascular risk.

60 Although there are different ways to assess a patient's ortho and retro-olfaction ^(17,18),
61 only 50% of ENTs assess the olfactory disorders on an anamnesis, and 10% assess through
62 psychophysical tests ⁽¹⁹⁾. Olfaction is most often evaluated by subjective self / hetero
63 questionnaires with a significant variability of the results and a probable
64 underestimation,^(19,20) given the poorer olfactory perception before 20 years and after 50
65 ^(21,22). Complete psychophysical olfactory tests, with assessment of odor threshold, odor
66 discrimination and odor identification, are the gold standard ⁽¹⁹⁾ and allow to specify the
67 olfactory disorder ⁽²³⁾. The most used in Europe is the Sniffin 'stick test® (SST)^(19,21,24-26) that
68 include an odor Threshold detection (T), an odor Discrimination (D) and an odor Identification
69 (I) tests. However, these psychophysical tests are expensive and take a long time (between 30
70 and 60 minutes))^(17,18), thus making their daily clinical use difficult. It therefore seems

71 important to look for other olfactory tests that are faster (≤ 5 minutes) and accessible to
72 specialists, but also to general practitioners.

73 The Sniffin 'Sticks Test - 12 items (SST-12) is an olfactory screening test in the form of
74 a 4-minute identification test allowing, according to its authors, to detect anosmia and
75 hyposmia with comparable measurement reliability other similar scent screening tests ^(27,28).
76 It can also be used laterally (one nostril tested independently of the other).

77 Seeing that it has been demonstrated that identification disorders are predominant in
78 post COVIDs ⁽⁵⁾, the objective of this study was to assess the value of SST-12 in the detection
79 and characterization of a persistent post-COVID-19 olfactory disorder.

80 MATERIAL AND METHODS

81

82 **Population**

83 The study was approved by the institutional review board of the Nice University
84 Hospital (CNIL number: 412). This study is part of a large work registered under a
85 ClinicalTrials.gov number (ID: NCT04799977). Since March 2020, we retrospectively
86 recruited at ENT department of Nice University Hospital all patients infected by COVID-19 with
87 persistent olfactory disorders from two to nine months. Patients were self-referred or
88 referred by colleagues, general practitioners or advised by the infectiology department that
89 managed all COVID-19 declared patients (city guidelines). Patients had either an olfactory
90 complaint for over 6 weeks and a molecular-proven SARS-CoV-2 diagnosis or a CT-proven
91 SARS-CoV-2 diagnosis secondarily confirmed by serology. We retrospectively extracted
92 patients' demographic data, and clinical characteristics including nasofibroscope, visual
93 analogue scale (VAS) for the subjective assessment of olfactory recovery (ranging from 0% to
94 100%), subjective taste impairment, over intake of salt and sugar, and SST^(26,29,30) total and
95 subdomains results which were systematically assessed. SST-12 results were extrapolated
96 from SST results.

97

98 **Sniffin' sticks test 12 items**

99 Olfaction diseases SST-12 test has been validated in 2001 by Hummel et al.⁽³¹⁾. This 4
100 min screening psychophysical test is an odor identification test based on 12 from the 16 odors
101 being sniffed during the identification subdomain part of the original SST.

102 The original SST identification odors set include peppermint, orange, fish, leather, rose,
103 cloves, coffee, pineapple, licorice, anise, lemon, banana, cinnamon, apple, turpentine and

104 garlic. During the identification SST test, subjects were blindfolded. Sixteen odorant sticks
105 were presented once, separated by an interval of at least 20 seconds to prevent olfactory
106 desensitization. Each stick presentation was accompanied by a written list containing the
107 correct odorant and 3 semantic distractors. Retrospectively, results from all odors set but
108 apple, turpentine, garlic and anise were summed up to the SST-12 global score, as previously
109 described⁽³¹⁾. We defined a normosmia ($SST-12 \geq 11$), an hyposmia ($10 > SST-12 > 6$) or an
110 anosmia ($SST-12 \leq 6$) based on normative values assessed from more than 1200 patients
111 assessed with SST and olfactive evoked potential for anosmic and hyposmic ones⁽³¹⁾. Apple,
112 turpentine and garlic have been removed from the SST-12 because identified by less than 55%
113 of its normosmic validation cohort⁽³¹⁾. Anise was removed too because of being too similar to
114 liquorice. With a reproducibility kappa coefficient of 0,77, the diagnosis agreement can be
115 considered as “good” (Altman, 1991). Although olfactory abilities decreased at extreme ages,
116 SST-12 can be used before the age of 10 and after the age of 80.

117

118 **Statistical Analysis**

119 Data are presented as mean (SD) for quantitative variables and as frequency and
120 percentage for qualitative variables. The degree of accordance between the SST and the SST-
121 12 in patients' categorization was calculated using Cohen's Kappa coefficient. Sensitivity and
122 specificity of the SST-12 compared to the SST in classifying patients as anosmic, was also
123 reported. To verify whether patients that increased their consumption of salt and sugar had
124 lower SST and SST-12 scores compared to those who did not, we employed Mann-Whitney U
125 tests. Chi2 tests were employed to explore links between self-reported taste disorders and
126 the presence of an increased salt and sugar consumption. To investigate correlations between
127 subjective reports (VAS), and odor identification disorders (based on the SST and SST-12) we

128 performed bivariate correlation analyses. As data were not normally distributed (as suggested
129 by Kolmogorov-Smirnov test), non-parametric Spearman's correlations were employed.

130

131

132 **Table 1** - Demographic and clinical characteristics. SD=standard deviation; CT=computerized
 133 tomography; PCR=polymerase chain reaction
 134

	n	%
Total	54	100
COVID₁₉ testing		
Molecular PCR test	46	85.2
Chest CT	11	20.4
Serology (antibody test)	16	29.6
COVID-19 dedicated treatment		
Oral corticosteroids	6	11.1
Nasal corticosteroids	4	7.4
Inhaled corticosteroids	2	3.7
Azithromycin alone	7	13.0
Hydroxychloroquine alone	1	1.9
Azithromycin + Hydroxychloroquine	3	5.5
Amoxicillin alone	1	1.9
Amoxicillin + Azithromycin	2	3.7
Others (vitamins, zinc)	5	9.3
	mean	SD
VAS (subjective % of olfactory recovery)	33.9	25.6
Sniffin' Sticks test – scores		
Threshold detection	4.7	4.0
Discrimination	10.3	3.1
Identification	9.4	3.9
Taste disorders	49	90.7
Retro-olfaction alone	35	64.8
Retro-olfaction + taste	12	22.2
Taste alone	1	1.8

135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168

169 **Table 2** – Categorization of subjects based on the Sniffin’ Sticks Test scores (SST), Sniffin’ Sticks
170 Test 12 items scores (SST12) and inter-test reliability (Kappa)

171

N=54	Normosmic	Hyposmic	Anosmic
	N(%)	N(%)	N(%)
SST	13(24,1)	29(53,7)	12(22,2)
SST-12	8(14,8)	26(48,1)	20(37,0)
<i>Correct Categorization</i>	4(7,4)	17(31,5)	12(22,2)
<i>False positive</i>	0(0)	9(16,7)	8(14,8)
<i>False negative</i>	4(7,4)	0(0)	0(0)
Cohen’s Kappa	0,242	0,224	0,654

172

173

174

175

176

177

178

179

180

181

182

183

184

185 **Table 3** - Sensitivity and specificity of the different cut-off scores of the SST-12 compared to
186 the SST in classifying patients as anosmic

	SST-12 score	Sensitivity	Specificity
187			
188	0	1,000	0,00
189	1	1,000	0,17
	2	1,000	0,25
190	3	0,98	0,33
191	4	0,93	0,42
192	5	0,88	0,75
	6	0,81	1,00
193	7	0,69	1,00
194	8	0,55	1,00
195	9	0,38	1,00
	10	0,19	1,00
196	11	0,07	1,00
197	12	0,00	1,00

198


199

200

201

202

203 **Figure 1.** Correlations between a) SST-12 and SST identification score, b) percentage of
204 subjective olfactory recovery (VAS) and SST, and c) percentage of subjective olfactory
205 recovery (VAS) and SST-12



207 RESULTS

208

209 Demographic and clinical features

210 Fifty-four patients consulting the ENT department of Nice University Hospitals (CHU)
211 for olfactory complaints after a COVID-19 infection were included in the study. The
212 demographic and clinical features are reported in Table 1. 57% of patients were female (n=31),
213 with a mean age of 39.9±13,9 years. They were seen after 5.4±3,1 months after the COVID-19
214 infection. 17 patients (31.5%) received a COVID-19 related treatment.

215

216 Retrospective olfactory and taste complains screening results

217 Descriptive analyses for the loss of smell and taste are reported in Table 2. The day of
218 consultation, patients reported to have recovered only 33.9±25.6% of their olfaction (ranging
219 from 0% to 90%). 90.7% of the patients (n=49) reported taste disorders, including retro-
220 olfaction (food flavors) alone (64.8%, n=35), retro-olfaction associated to taste (22.2%, n=12;
221 16.7% concerning sweet and salty, 11.1% concerning sour and bitter), or taste alone (1.8%,
222 n=1 concerning sweet and salty). 45.5% of patients (20 out of the 44 who responded to the
223 question) reported that they increased their consumption of salt, and 20.5% (9 out of 44)
224 that they increased their consumption of sugar.

225 Categorization of patients based on the results of the olfactory tests is presented in
226 Table 2. The global results (TDI) of the Sniffin' Sticks Test (SST) suggested that 24,1% (n=13) of
227 the patients could be classified as normosmic (TDI≥30.75), 53,7% (n=29) as hyposmic
228 (16.25≤TDI≤30.5) and 22,2% (n=12) as functional anosmic (TDI≤16). Based on the SST-12,
229 14,8% (n=8) of the patients could be classified as normosmic (SST-12≥11), 48,1% (n=26) as
230 hyposmic (6< SST-12<10) and 37% (n=20) as functional anosmic (SST-12≤6). Interestingly,

231 patients that increased their consumption of salt showed lower SST ($U=112.5$, $p=0.003$) and
232 SST-12 ($U=121$, $p=0.005$) scored compared to the patients that did not increase salt usage
233 (20.0 ± 8.8 vs. 27.9 ± 7.7 , and 5.7 ± 3.5 vs. 8.5 ± 2.2 , respectively). The same result was found for
234 patients who increased their consumption of sugar, that showed lower SST ($U=73.5$,
235 $p=0.014$) and SST-12 ($U=62$, $p=0.005$) scored compared to the other patients (26.2 ± 8.0 vs.
236 17.1 ± 8.4 , and 4.6 ± 2.9 vs. 6.9 ± 2.9 , respectively). The self-reported presence of taste disorders
237 did not show any significant link with the presence of an increased consumption of salt
238 ($\text{Chi}^2=0.74$, $p=389$) or sugar ($\text{Chi}^2=1.13$, $p=287$).

239 Taking SST as the *gold standard*, on 54 patients, 61% ($n=33$) were classified in the same
240 category by the SST-12 patients. SST-12 misdiagnosed 4 patients as normosmic (7.4%), 8 as
241 anosmic (14.8%), and 9 as hyposmic (16.7%). Importantly, all the patients that were diagnosed
242 as anosmic by the SST were also detected by the SST-12. Accordingly, Cohen's Kappa
243 coefficient revealed a weak agreement between the two tests in classifying patients as
244 normosmic (Kappa= 0.24) and hyposmic (Kappa=0.22), but a strong agreement in classifying
245 patients as anosmic (Kappa=0.65). The sensitivity and specificity of the SST-12, compared to
246 the SST score, is reported in Table 3 and suggests that a score of 6 is the cut-off that maximize
247 the combination between specificity (100%) and sensitivity (81%) in detecting anosmic
248 patients. The presence of taste disorders did not affect the type of errors of the SST-12
249 compared to the SST.

250

251 **Correlations between self-reported olfactory recovery, SST and SST-12 score**

252 VAS scores were $45\pm 24\%$ (range 5%-70%), $38\pm 25\%$ (range 1%-90%), and $13\pm 16\%$ (range
253 0%-50%) for respectively normosmic, hyposmic and anosmic patients, based on the SST. Based
254 on the SST-12, VAS scores were $52\pm 26\%$, $42\pm 22\%$, and $16\pm 19\%$ for respectively normosmic,

255 hyposmic and anosmic patients. An almost perfect correlation between scores at the SST and
256 SST-12 was found ($\rho_{(52)}=0.98$, $p<0.001$), confirming that the SST-12 can assess odor
257 identification as well as the SST. Correlations between subjective reports (VAS) and the SST
258 and SST-12 scores suggested a significant, positive correlation between percentage of
259 subjective olfactory recovery (VAS) and the identifications scores for both the SST
260 ($\rho_{(52)}=0.47$, $p<0.001$) and the SST-12 scores ($\rho_{(52)}=0.49$, $p<0.001$), testifying that the two
261 scales were equally correlated to self-reported disorders. These results are reported in Figure
262 1.
263
264

265 **DISCUSSION**

266 This is the first study that evaluates quantitatively the efficiency of the SST-12 to screen
267 for post-COVID-19 olfactory disorders, and specially to identify post COVID-19 anosmics
268 patients.

269 Screening for olfactory disorders is important because, in addition to allowing to set
270 up appropriate care for patients, it helps prevent the occurrence of consequences of long-
271 term anosmia like an alteration in the quality of life⁽⁵⁾ , psychiatric disorders such as
272 depression^(6,7), anxiety, anorexia⁽⁸⁾ and its nutritional consequences⁽⁹⁾, social interaction
273 disorders^(10,11) or cognitive impairment^(10,12,13). Although a subjective olfactory complaint (80%
274 anosmia, 20% hyposmia) is now a very frequent symptom of a COVID-19 infection ⁽²⁾ affecting
275 70 to 85% of patients ^(32,33), only 21% of clinicians use psychophysical olfactory tests to
276 characterize this olfactory complaint ⁽²⁰⁾. Odor disorder is also the only symptom in 16-20% of
277 cases ^(3,34).

278 Post-COVID-19 olfactory disorders show unique psychophysical characteristics in the
279 long term. In a population of 34 patients deprived of their olfaction for about 6 months after
280 COVID-19 and presenting a persistent odor complaint (VAS), we previously highlighted a
281 significantly predominant impairment of odor identification⁽⁵⁾, characteristic of central
282 olfactory impairment ⁽²³⁾. This impairment worsened with the duration of olfactory
283 deprivation and significantly impacted the quality of life.

284 The present study shows the reliability of SST-12 in screening for post-COVID-19
285 olfactory disorders, and in particular anosmia. Among SST-12 diagnostic errors, only 7% (n =
286 4) of hyposmic patients would have been considered normosmic by the gold standard (SST).
287 The other differences in scores between the SST-12 and the SST do not modify the purpose of
288 the screening, which is to perform or have performed complete olfactory tests in the event of

289 an abnormality detected. In this way, all but 4 patients (92%) would have been correctly
290 screened using the SST-12. All the anosmics patients at the SST were correctly screened by the
291 SST-12 as evidenced by the "good" correlation coefficient ($0,61 \leq \text{Kappa} \leq 0,80$ - Altman 1991).
292 Other screening test do exist. The Q-stick test^(35,36) is another olfactory screening test validated
293 on 196 people from the SST. It allows, after the age of 12, to assess the identification of three
294 smells (coffee, cloves and rose) contained again in olfactory markers. On the other hand, its
295 reliability coefficient is less good than the SST-12 (Kappa between 0.2 and 0.33 at most)⁽³⁶⁾.
296 Also, it does not detect 8% of anosmics according to its authors⁽³⁶⁾. Others are more used in
297 Asia or the American continent (Cross Cultural Smell Identification Test (CC-SIT)⁽²⁷⁾, Q-SIT⁽²⁸⁾)
298 but they are based on single-use "scratch and sniff". Others are less used⁽¹⁷⁾ (Kremer olfactory
299 Test, Le Nez du Vin, Smell Diskettes). They require additional specific equipment (Jet Stream
300 Olfactometer) or have been validated outside of Europe (different scents) or on small cohorts,
301 and never in the context of COVID-19.

302 The total SST-12, as SST, was significantly correlated ($p < 0.001$) with odor complaint
303 (VAS – figure 1) which reflects persistent post-COVID-19 olfactory impairment, i.e.
304 identification disorder⁽⁵⁾. Unlike the SST, the SST-12 only assesses the identification of odors
305 and thus seems more suited to detect an identification disorder than the SST, which adds to
306 the identification score, a score for discrimination and perception of the odor threshold. As
307 we have shown in previous studies⁽⁵⁾, the SST interpretation can conclude to a global
308 normosmia when one of its subdomains is altered. The SST should therefore not be used as a
309 gold standard in the post-COVID-19 odor evaluation given that some patients, early⁽³⁷⁾ and at
310 a distance⁽⁵⁾ from SARS-COV-2 infection, may be incorrectly classified as normosmic on SST
311 despite odor loss⁽⁵⁾. In this study we found that olfactory complain (VAS) was significantly
312 linked to an SST or SST12 impairment, justifying the no need to a psychophysical screening

313 test to take social distancing and barrier measures in case of acute olfactory disorders in
314 COVID-19 pandemic times. Even if SST-12 has been recently evaluated in a single-use "filter
315 paper" manner⁽³⁸⁾, 7% of hyposmic patients could be missed with such a test. This is especially
316 true since such a screening test poses a contamination risk to the examiner. However, at a
317 distance from acute infection, SST-12 could be helpful to screen post COVID-19 olfactory
318 disorders. In case of a complaining person, as our results suggest, a complete psychophysical
319 olfactory test might be directly performed as an olfactory complain is highly correlated with
320 an impaired SST and SST-12. But in case of a non-complaining, or olfactory impairment
321 unaware, post-COVID-19 patient, SST-12 could avoid negative consequences of unknown
322 olfactory disorders, especially quality of life^(5,39-41) and metabolic impairments. Indeed, 45,5
323 and 20,5% (n=44) of post COVID-19 patients increased respectively their daily diet salt and
324 sugar intake. As previously published, salt and sugar intake increase concerned near 30% of
325 COVID-19 patients⁽¹⁵⁾, especially young women. Our results suggest that these bad diet habits
326 could be concerned in fact olfactory impaired post-COVID-19 patients, specifically anosmics ones
327 (SST-12≤6) being deprived of their original food tastes and trying to enhance it whatever the
328 way. Interestingly, there is no significant relation, otherwise only with the SST-12 score,
329 between the risk of bad diet habits and subjective olfactory complain, underlining the benefits
330 of using SST-12. The sugar intake is also concerned as COVID-19 could basically raise blood
331 glucose and HbA1c levels⁽⁴²⁾ which has to be monitored after hospital discharge. It's a major
332 public health concern as post-COVID-19 olfaction disorders recovery time is still uncertain and
333 long term salt and sugar intake could increase respectively blood pressure⁽⁴³⁾ and type 2
334 diabetes⁽⁴⁴⁾ onset and so, cardiovascular risk. In case of SST-12 screened anosmia, a not to
335 change daily use of salt and sugar advice must be added to the patient consultation.

336 Despite these interesting results, this study suffers from some limitations. The main
337 limitation concerns the small cohort of 54 patients, with no follow up reported, who
338 spontaneously consulted our university hospital, which represents the risk of a recruitment
339 bias. The small sample size may have contributed to a limited strength of correlations ($\rho(32)$
340 $\text{MAX} = 0,49$), and therefore our results cannot be directly generalized to all patients with a
341 post-covid olfactory disorder and could be verified in a larger prospective cohort study.

342

343 **CONCLUSION**

344 The SST 12 is an olfactory psychophysical test suitable for screening an olfactory sequelae post
345 COVID-19. It makes it possible to highlight the subjective complaint of patients on the odor's
346 identification. Its use in the context of screening for a long olfactory covid could be used for
347 the implementation of personalized management of olfactory disorders and the prevention
348 of psychological and metabolic consequences adding to the impairment of quality of life.

349

350

351

352 REFERENCES

- 353 1. Gerkin RC, Ohla K, Veldhuizen MG, et al. Recent Smell Loss Is the Best Predictor of
354 COVID-19 Among Individuals With Recent Respiratory Symptoms. *Chem Senses*.
355 2021;46(December 2020):1–12.
- 356 2. Gane SB, Kelly C, Hopkins C. Isolated Sudden Onset Anosmia in COVID-19 Infection. A
357 Novel Syndrome? *Rhinol J*. 2020;58(3):299–301.
- 358 3. Carrillo-Larco RM, Altez-Fernandez C. Anosmia and dysgeusia in COVID-19: A
359 systematic review. *Wellcome Open Res*. 2020;5:94.
- 360 4. Kanjanaumporn J, Aeumjaturapat S, Snidvongs K, Seresirikachorn K, Chusakul S. Smell
361 and taste dysfunction in patients with SARS-CoV-2 infection: A review of
362 epidemiology, pathogenesis, prognosis, and treatment options. *Asian Pacific J Allergy*
363 *Immunol*. 2020;69–77.
- 364 5. Vandersteen C, Payne M, Dumas L-E, et al. Persistent olfactory complaints after
365 COVID-19: a new interpretation of the psychophysical olfactory scores. *Rhinol Online*.
366 2021;4(14):66–72.
- 367 6. Hur K, Choi JS, Zheng M, Shen J, Wrobel B. Association of alterations in smell and taste
368 with depression in older adults. *Laryngoscope Investig Otolaryngol*. 2018;3(2):94–9.
- 369 7. Kohli P, Soler ZM, Nguyen SA, Muus JS, Schlosser RJ. The Association Between
370 Olfaction and Depression: A Systematic Review. *Chem Senses*. 2016;41(6):479–86.
- 371 8. Croy I, Nordin S, Hummel T. Olfactory disorders and quality of life-an updated review.
372 *Chem Senses*. 2014;39(3):185–94.
- 373 9. Nordin S. Sensory perception of food and ageing. In: *Food for the Ageing Population*.
374 Elsevier; 2009. p. 73–94.
- 375 10. Valsamidis K, Printza A, Constantinidis J, Triaridis S. The Impact of Olfactory

- 376 Dysfunction on the Psychological Status and Quality of Life of Patients with Nasal
377 Obstruction and Septal Deviation. *Int Arch Otorhinolaryngol.* 2020;24(02):e237–46.
- 378 11. Schablitzky S, Pause BM. Sadness might isolate you in a non-smelling world: olfactory
379 perception and depression. *Front Psychol.* 2014;5(FEB).
- 380 12. Nordin S, Brämerson A. Complaints of olfactory disorders: epidemiology, assessment
381 and clinical implications. *Curr Opin Allergy Clin Immunol.* 2008;8(1):10–5.
- 382 13. Ahmedy F, Mazlan M, Danaee M, Abu Bakar MZ. Post-traumatic brain injury olfactory
383 dysfunction: factors influencing quality of life. *Eur Arch Oto-Rhino-Laryngology.*
384 2020;277(5):1343–51.
- 385 14. Hopkins C, Surda P, Vaira LA, et al. Six month follow-up of self-reported loss of smell
386 during the COVID-19 pandemic. *Rhinol J.* 2020;(11):0–0.
- 387 15. Rolland B, Haesebaert F, Zante E, Benyamina A, Haesebaert J, Franck N. Global
388 Changes and Factors of Increase in Caloric/Salty Food Intake, Screen Use, and
389 Substance Use During the Early COVID-19 Containment Phase in the General
390 Population in France: Survey Study. *JMIR Public Heal Surveill.* 2020;6(3):e19630.
- 391 16. Boscolo P, Francesco R, Jerry G, et al. Self - reported smell and taste recovery in
392 coronavirus disease 2019 patients : a one - year prospective study. *Eur Arch Oto-*
393 *Rhino-Laryngology.* 2021;(0123456789).
- 394 17. Doty RL. Office Procedures for Quantitative Assessment of Olfactory Function. *Am J*
395 *Rhinol.* 2007;21(4):460–73.
- 396 18. Su B, Bleier B, Wei Y, Wu D. Clinical Implications of Psychophysical Olfactory Testing:
397 Assessment, Diagnosis, and Treatment Outcome. *Front Neurosci.* 2021;15(March):1–
398 12.
- 399 19. Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory dysfunction.

- 400 Rhinol J. 2017;54(26):1–30.
- 401 20. Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and Taste
402 Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. Mayo
403 Clin Proc. 2020;95(8):1621–31.
- 404 21. Oleszkiewicz A, Schriever VA, Croy I, Hähner A, Hummel T. Updated Sniffin' Sticks
405 normative data based on an extended sample of 9139 subjects. Eur Arch Oto-Rhino-
406 Laryngology. 2019;276(3):719–28.
- 407 22. Sorokowska A, Schriever VA, Gudziol V, et al. Changes of olfactory abilities in relation
408 to age: odor identification in more than 1400 people aged 4 to 80 years. Eur Arch Oto-
409 Rhino-Laryngology. 2015;272(8):1937–44.
- 410 23. Whitcroft KL, Cuevas M, Haehner A, Hummel T. Patterns of olfactory impairment
411 reflect underlying disease etiology. Laryngoscope. 2017;127(2):291–5.
- 412 24. Gudziol V, Lötsch J, Hähner A, Zahnert T, Hummel T. Clinical significance of results
413 from olfactory testing. Laryngoscope. 2006;116(10):1858–63.
- 414 25. Steinbach S, Hummel T, Böhner C, et al. Qualitative and Quantitative Assessment of
415 Taste and Smell Changes in Patients Undergoing Chemotherapy for Breast Cancer or
416 Gynecologic Malignancies. J Clin Oncol. 2009;27(11):1899–905.
- 417 26. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. 'Sniffin' Sticks': Olfactory
418 Performance Assessed by the Combined Testing of Odour Identification, Odor
419 Discrimination and Olfactory Threshold. Chem Senses. 1997;22(1):39–52.
- 420 27. Doty RL, Marcus A, William Lee W. Development of the 12-Item Cross-Cultural Smell
421 Identification Test(CC-SIT). Laryngoscope. 1996;106(3):353–6.
- 422 28. Jackman AH, Doty RL. Utility of a Three-Item Smell Identification Test in Detecting
423 Olfactory Dysfunction. Laryngoscope. 2005;115(12):2209–12.

- 424 29. Allis TJ, Leopold DA. Smell and Taste Disorders. *Facial Plast Surg Clin North Am.*
425 2012;20(1):93–111.
- 426 30. Rumeau C, Nguyen DT, Jankowski R. Comment tester l'olfaction avec le Sniffin' Sticks
427 test®. *Ann françaises d'Oto-rhino-laryngologie Pathol Cervico-faciale.*
428 2016;133(3):183–6.
- 429 31. Hummel T, Rosenheim K, Konnerth C-G, Kobal G. Screening of Olfactory Function with
430 a Four-Minute Odor Identification Test: Reliability, Normative Data, and Investigations
431 in Patients with Olfactory Loss. *Ann Otol Rhinol Laryngol.* 2001;110(10):976–81.
- 432 32. Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological
433 characteristics of 1420 European patients with mild-to-moderate coronavirus disease
434 2019. *J Intern Med.* 2020;288(3):335–44.
- 435 33. Lechien JR, Cabaraux P, Chiesa-Estomba CM, et al. Objective olfactory evaluation of
436 self-reported loss of smell in a case series of 86 COVID-19 patients. *Head Neck.*
437 2020;42(7):1583–90.
- 438 34. Lechien JR, Hopkins C, Saussez S. Sniffing out the evidence; It's now time for public
439 health bodies recognize the link between COVID-19 and smell and taste disturbance.
440 *Rhinol J.* 2020;10(7):0–0.
- 441 35. Hummel T, Pfetzing U, Lötsch J. A short olfactory test based on the identification of
442 three odors. *J Neurol.* 2010;257(8):1316–21.
- 443 36. Sorokowska A, Oleszkiewicz A, Minovi A, Konnerth CG, Hummel T. Fast Screening of
444 Olfactory Function Using the Q-Sticks Test. *ORL.* 2019;81(5–6):245–51.
- 445 37. Lechien JR, Cabaraux P, Chiesa-Estomba CM, et al. Psychophysical Olfactory Tests and
446 Detection of COVID-19 in Patients With Sudden Onset Olfactory Dysfunction: A
447 Prospective Study. *Ear, Nose Throat J.* 2020;99(9):579–83.

- 448 38. Wirkner K, Hinz A, Loeffler M, Engel C. Sniffin' Sticks Screening 12 test: Presentation of
449 odours on filter paper improves the recognition rate. *Rhinol J.* 2021;0–0.
- 450 39. Liu DT, Besser G, Prem B, et al. Self-perceived Taste and Flavor Perception:
451 Associations With Quality of Life in Patients With Olfactory Loss. *Otolaryngol Neck*
452 *Surg.* 2020;019459982096524.
- 453 40. Elkholi SMA, Abdelwahab MK, Abdelhafeez M. Impact of the smell loss on the quality
454 of life and adopted coping strategies in COVID-19 patients. *Eur Arch Oto-Rhino-*
455 *Laryngology.* 2021;(0123456789).
- 456 41. Coelho DH, Reiter ER, Budd SG, Shin Y, Kons ZA, Costanzo RM. Quality of life and
457 safety impact of COVID-19 associated smell and taste disturbances. *Am J Otolaryngol.*
458 2021;42(4):103001.
- 459 42. Chen J, Wu C, Wang X, Yu J, Sun Z. The Impact of COVID-19 on Blood Glucose: A
460 Systematic Review and Meta-Analysis. *Front Endocrinol (Lausanne).*
461 2020;11(October):1–8.
- 462 43. Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high
463 sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and
464 triglyceride. *Cochrane Database Syst Rev.* 2017;2017(4).
- 465 44. Lean MEJ, Te Morenga L. Sugar and type 2 diabetes. *Br Med Bull.* 2016;120(1):43–53.
466